MedTrace Logo

A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer

NCT01196247 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2012-07-17

No results posted yet for this study

Summary

The purpose of the study is selecting second line therapy for patients with pancreatic cancer using molecular profiling will improve 1 year survival.

Conditions

  • Previously Treated Metastatic Pancreatic Cancer

Interventions

DRUG

Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank

FDA approved drugs as indicated by molecular profiling

Sponsors & Collaborators

Principal Investigators

  • Ramesh Ramanathan, MD · TGen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-11-30
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01196247 on ClinicalTrials.gov